Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes three candidates currently in clinical development: PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, and a preclinical oral candidate targeting SMARCA2.
Company Details
- Employees
- 135
- Founded
- 2016
- Address
- 175 Innovation Boulevard, Wilmington,de 19805,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.preludetx.com/
- Keywords
- Oncology, Cancer therapeutics, Precision medicines, Biotech, Precision oncology, Cancer Research, small molecule therapies, cancer biology.
- HQ
- Wilmington, DE
Prelude Therapeutics Questions
Prelude Therapeutics's website is http://www.preludetx.com/
Prelude Therapeutics's LinkedIn profile is https://www.linkedin.com/company/prelude-therapeutics
Prelude Therapeutics has
135 employees.
View email and phone details for 135
employees at Prelude Therapeutics.
Prelude Therapeutics's industry is
Biotechnology Research
Prelude Therapeutics's top competitors are
Quanta Therapeutics,
Vertex Pharmaceuticals,
Incyte,
Synnovation Therapeutics,
Nurix Therapeutics,
Allogene Therapeutics,
Scorpion Therapeutics,
Nikang Therapeutics Inc.,
Halda Therapeutics,
Arcus Biosciences.
Prelude Therapeutics's categories are Biotechnology Research
Prelude Therapeutics's founding year is 2016
